Author
Listed:
- Chao Yang
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Qingxiao Fang
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Mengyu Li
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Jin Zhang
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Rui Li
(Tianjin University of Science and Technology)
- Tianxing Zhou
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Keshan Wang
(Huazhong University of Science and Technology)
- Jie Deng
(Huazhong University of Science and Technology)
- Xiuchao Wang
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Chongbiao Huang
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Yukuan Feng
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Xiaoping Zhang
(Huazhong University of Science and Technology)
- Lei Shi
(State Key Laboratory of Experimental Hematology
Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education)
Key Laboratory of Immune Microenvironment and Disease (Ministry of Education)
The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics)
- Changhao Bi
(Chinese Academy of Sciences)
- Xueli Zhang
(Chinese Academy of Sciences)
- Jun Yu
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
- Jihui Hao
(Tianjin Medical University Cancer Institute and Hospital
National Clinical Research Center for Cancer
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine
Tianjin Key Laboratory of Digestive Cancer)
Abstract
Prime editing (PE) is a precise tool for introducing genetic mutations in eukaryotes. Extending the efficient editing scope and mitigating undesired byproducts are possible. We introduce reverse PE (rPE), a SpCas9-directed variant that enabled DNA editing at the 3′ direction of HNH-mediated nick site. The rPE leveraging nCas9-D10A and rPE gRNA targeting the 5′ direction of HNH-mediated nick site inscribes genetic alterations, achieving a reverse editing window and potentially high fidelity. HNH and reverse transcriptase engineered using protein language models in conjunction with La facilitate circular erPEmax and erPE7max, achieving editing efficiency up to 44.41% without nick gRNA or positive selection. Furthermore, our findings underscore the capability of rPE in inserting functionally enhanced variant (PIK3CDE527G) for cell therapy. By expanding the editing scope and enhancing genomic manipulability, rPE represents a meaningful advancement in prime editing, improving its utility for research and therapeutic applications.
Suggested Citation
Chao Yang & Qingxiao Fang & Mengyu Li & Jin Zhang & Rui Li & Tianxing Zhou & Keshan Wang & Jie Deng & Xiuchao Wang & Chongbiao Huang & Yukuan Feng & Xiaoping Zhang & Lei Shi & Changhao Bi & Xueli Zhan, 2025.
"Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity,"
Nature Communications, Nature, vol. 16(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60495-w
DOI: 10.1038/s41467-025-60495-w
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60495-w. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.